2013 Fiscal Year Final Research Report
Development of a novel comprehensive therapy targeting aurora kinase-A for adult T cell leukemia
Project/Area Number |
23591419
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Hematology
|
Research Institution | Ehime University |
Principal Investigator |
AZUMA Taichi 愛媛大学, 医学部附属病院, 講師 (10396252)
|
Co-Investigator(Renkei-kenkyūsha) |
YASUKAWA Masaki 愛媛大学, 大学院医学系研究科, 教授 (60127917)
|
Project Period (FY) |
2011 – 2013
|
Keywords | 造血器腫瘍 / 細胞免疫療法 |
Research Abstract |
In this study, aiming at a development of novel adoptive immunotherapy against adult T-cell leukemia (ATL) which is one of the most treatment-refractory T-lymphoid malignancy, we newly demonstrated the clinical feasibility of adoptive immunotherapy targeting human telomerase reverse transcriptase (hTERT) for the treatment of ATL, and also demonstrated the potential advantage of Aurora kinase-A (AURKA) as a novel therapeutic target for ATL. In addition, we started to extend our therapeutic strategy against ATL from that based on T-cell receptor gene-modified T-cell to newly designed chimeric receptor gene-modified T cell-based one.
|
-
-
[Journal Article] Development of a novel redirected T-cell-based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia2013
Author(s)
Miyazaki Y, Fujiwara H, Asai H, Ochi F, Ochi T, Azuma T, Ishida T, Okamoto S, Mineno J, Kuzushima K, Shiku H, Yasukawa M
-
Journal Title
Blood
Volume: 121(24)
Pages: 4894-901
Peer Reviewed
-
-
-
-
-
-